Digital Health Innovator Eko Health Secures $41M in Funding to Revolutionize Heart and Lung Disease Detection

Eko Health has successfully raised $41 million in funding to further propel its groundbreaking digital health technology. The company, known for its innovative digital stethoscopes and AI detection platform SENSORA™, is revolutionizing how healthcare professionals detect and monitor heart and lung diseases. With its FDA-cleared technologies, Eko Health enables healthcare providers globally to diagnose with greater accuracy and confidence, manage treatments effectively, and deliver superior patient care. The funding round, led by investors such as Highland Capital Partners and Mayo Clinic, among others, brings Eko Health's total funding to over $125 million. This significant financial boost will empower the company to expand its product offerings, enhance its AI capabilities, and strengthen its position as a leader in transforming healthcare through cutting-edge technology. Eko Health's commitment to advancing healthcare by providing clinicians with state-of-the-art tools underscores its dedication to improving patient outcomes and revolutionizing the medical industry.